Sunitha Lakshminarayanan

Sunitha Lakshminarayanan has more than 25 years of biopharmaceutical development, manufacturing and commercialization experience across cell therapy, biologics, biosimilars, radioligand therapies, vaccines, oral solid dose products and injectables. Most recently, as CTO of Melinta Therapeutics, she led Manufacturing, Quality, Supply Chain and Technical Operations for a global commercial portfolio, driving significant improvements in cost, supply reliability and operational performance. As SVP at Actinium Pharmaceuticals, she led CMC and Technical Operations for a clinical-stage radiopharmaceutical portfolio. At Bristol Myers Squibb/Celgene, she built and led a 50-person global cell therapy Process Engineering organization and directed process validation, comparability and manufacturing readiness supporting the approvals of Breyanzi® and Abecma®. At Kashiv BioSciences, she led development and manufacturing activities for biosimilars, including the development and FDA approvals of Releuko® and Fylnetra®. Earlier roles at Progenics and BioReliance included biologics and vaccine development, clinical manufacturing and technology transfer. She holds an MBA from Northwestern University’s Kellogg School of Management, an M.S. in Chemical Engineering from Penn State University, and a B.S. in Chemical Engineering from Coimbatore Institute of Technology.